- Home
- VRSK vs TAK Comparison
VRSK vs TAK Comparison
Compare VRSK & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRSK
- TAK
- Stock Information
- Founded
- VRSK 1971
- TAK 1781
- Country
- VRSK United States
- TAK Japan
- Employees
- VRSK N/A
- TAK N/A
- Industry
- VRSK Business Services
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- VRSK Consumer Discretionary
- TAK Health Care
- Exchange
- VRSK Nasdaq
- TAK Nasdaq
- Market Cap
- VRSK 40.9B
- TAK 47.0B
- IPO Year
- VRSK 2009
- TAK N/A
- Fundamental
- Price
- VRSK $309.50
- TAK $14.37
- Analyst Decision
- VRSK Hold
- TAK
- Analyst Count
- VRSK 10
- TAK 0
- Target Price
- VRSK $296.90
- TAK N/A
- AVG Volume (30 Days)
- VRSK 818.9K
- TAK 2.1M
- Earning Date
- VRSK 05-07-2025
- TAK 05-08-2025
- Dividend Yield
- VRSK 0.58%
- TAK 4.10%
- EPS Growth
- VRSK 27.61
- TAK N/A
- EPS
- VRSK 6.84
- TAK 0.45
- Revenue
- VRSK $2,930,700,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- VRSK $8.62
- TAK $0.87
- Revenue Next Year
- VRSK $7.16
- TAK $1.69
- P/E Ratio
- VRSK $45.57
- TAK $63.69
- Revenue Growth
- VRSK 7.20
- TAK 7.45
- 52 Week Low
- VRSK $243.28
- TAK $12.58
- 52 Week High
- VRSK $312.48
- TAK $15.37
- Technical
- Relative Strength Index (RSI)
- VRSK 64.82
- TAK 40.48
- Support Level
- VRSK $290.99
- TAK $14.22
- Resistance Level
- VRSK $312.82
- TAK $15.43
- Average True Range (ATR)
- VRSK 6.48
- TAK 0.20
- MACD
- VRSK 2.14
- TAK -0.08
- Stochastic Oscillator
- VRSK 88.79
- TAK 11.98
About VRSK Verisk Analytics Inc.
Verisk Analytics is the leading provider of statistical, actuarial, and underwriting data for the United States' property and casualty insurance industry. Verisk leverages a vast contributory database and proprietary data assets to develop analytical tools helping insurance providers to better assess and price risk, achieve operational efficiency and optimize claim settlement processes. While Verisk also offers tools to quantify costs after loss events occur and to detect fraudulent activity, it is expanding into adjacent markets of life insurance, marketing, and non-US operations.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.